About Us

Corporate Vision

Dedicated to developing and exploring groundbreaking, innovative therapies that fulfill our commitment to patients, employees and society.

Corporate Vision

Dedicated to developing and exploring groundbreaking, innovative therapies that fulfill our commitment to patients, employees and society.

Corporate Values

Continuous innovation, pursuit of excellence, teamwork, employee growth, adherence to integrity, social responsibility

Corporate Values

Continuous innovation, pursuit of excellence, teamwork, employee growth, adherence to integrity, social responsibility

Enterprise achievements and honors

National High-tech Enterprise, National Joint Laboratory, Beijing "Specialized, Specialized and New" Small and Medium-sized Enterprises, Beijing "Innovative" Small and Medium-sized Enterprises, 2023 Belt and Road High Quality Development Leader in Health Industry, Leader of Beijing Science and Innovation Consortium of Beijing Municipal Association for Science and Technology Beijing Neural Repair Industry Innovation Center, Beijing Intellectual Property Pilot Unit, Intellectual Property Management System Certification, Intellectual Property Gradient Cultivation Certificate, and New Quality Productivity Enterprise.

Enterprise achievements and honors

Beijing Darwin Cell Biotechnology Co.

Beijing Darwin Cell Biotechnology Co., Ltd. was founded in 2016, is a national high-tech enterprise; Beijing specializes in small and medium-sized enterprises;Lead unit of Beijing Municipal Association for Science and Technology's Science and Innovation Consortium (the first biomedical enterprise to take the lead); Preparatory unit of Beijing Neural Repair Industry Innovation Center; Co-unit of the Joint Laboratory for Translation of Acromegaly and Neural Repair Technology of Beijing Tiantan Hospital (National Medical Center for Neurological Diseases).

Darwin is a high-tech enterprise focusing on innovative biotechnology research and development, focusing on stem cells, exosomes, as well as self-developed ECIWEP protein polymer extraction technology, the company has a Darwin Center Laboratory, Darwin Clinical Laboratory, Darwin production process pilot laboratory three GMP laboratories; three wholly-owned subsidiaries were involved in two key directions for biopharmaceuticals and biological consumables. And biological consumables, another wholly owned subsidiary for the production-oriented enterprises with a complete GMP lyophilization products linked production line to undertake the company's consumables company's production work; the company focuses on nerve repair, articular cartilage repair, organ repair in the field of innovative biomedical product research and development. Indications for stroke, acromegaly, Alzheimer's and other neurodegenerative diseases.

Alitol, the first new Bio-1 drug under development, has shown breakthrough efficacy and good safety. 2023 saw the launch of the "Necklace Technology" research project at Beijing Tiantan Hospital (National Center for Neurological Diseases) and the launch of the double-blind clinical trial of "IIT" for the rare disease "Acromegaly". In 2023, we launched the research project of "necklace technology" at Beijing Tiantan Hospital (National Medical Center for Neurological Diseases), and initiated the double-blind clinical trial of "IIT" for rare diseases such as acromegaly.

R&D-driven innovative biotechnology R&D platform-based enterprise
Specialized in drug discovery and development in the field of repair
Specialized R&D investment in neurology, orthopedics, skin, oncology, rare diseases, etc.
Rich R&D pipeline of innovative substances

DARWIN Milestones

- 2016 Beijing Darwin Cell Biotechnology Co.
- 2017 Establishment of Clinical Center - Mayo Yee Woo Clinic, Purple Whale Medical Management Consulting Co.
- 2018 Completion of the Alitol process study
- 2019
  - Completion of Alitol sympathetic dosing in the first neuroprosthetic patient
  - Establishment of the second laboratory located in the Second Affiliated Hospital of Tsinghua University
- 2020
  - Conducting clinical studies on liver, kidney, brain and other organ damage caused by the new coronavirus
  - Cooperating medical institutions: General Hospital of the People's Liberation Army in Beijing, Shiyan Taihe Hospital in Hubei, Guizhou Provincial People's Hospital
- 2021
  - Establishment of an alitrole-based protein polymer research platform ECIWEP technical validation
  - Novel single strain and consortium named "Darwin Bio" complete national micro-⽣ species collection
  - Established a wholly-owned subsidiary, Darwin New Research (Beijing) Biotechnology Co.
  - Established a wholly owned subsidiary, Darwin Beginnings (Beijing) Biopharmaceutical Co.
  - Established a wholly owned subsidiary, Darwin Ray (Beijing) Biotechnology Co.
- 2022
  - Obtained the title of national high-new technology enterprise
  - Established Darwin Nogol (Beijing) Biotechnology Co.
  - Clinical Trial of Recombinant Collagen Spokes Material Launched
- 2023
  - Completed corporate reorganization - Serious Medicine and Consumer Medicine segments
  - Alitol, an innovative biological agent®Program Launched for the Treatment of Alzheimer's Disease (ALS)
  - Innovative Biological Agent Alitol Launches Technology Tackling Properties "Necklace" Project - "Safety and Preliminary Efficacy Study of Alitol in the Treatment of Patients with Amyotrophic Lateral Sclerosis".
  - Innovative Biological Agent Alitol Launched the "Necklace" Project of Technology Tackling Properties - "Preclinical Pharmacodynamic Study on the Protective Effect of Alitol on Ischemic Stroke". The
  - Completion of the pre-approval of Beijing Neural Repair Industry Innovation Center
  - Led the establishment of the Beijing Neural Repair Industry Synergy Consortium
  - Establishment of the Science and Technology Association of Beijing Darwin Cell Biotechnology Co.
- 2024
  - together withBeijing Tiantan Hospital of Capital Medical University Establishes Joint Laboratory for Translational Translation of Tachyphylaxis and Neural Repair Technology
  - Establishment of Wings of the Wind Specialized Charity Fund
  - Launch of Alzheimer's Disease Clinical Study
  - together withThe School of Basic Medical Sciences, Peking University School of Medicine, jointly conducted a project entitled "Efficacy and molecular study of mesenchymal stem cell-derived biologics in autism model rats".
  - Joint project with Fudan University, Shanghai, China, entitled "Functional study of the effects of alitol on growth and development and autism-related behaviors in the model organism zebrafish".
  - Establishment of Organoid (Brain) Drug Screening Platform with Bozhen Biotechnology (Suzhou) Co.

Lead operating agency

Beijing Neural Repair Industry Synergy Consortium

The science and innovation consortium will target the nerve repair industry, unite the upstream and downstream of the industrial chain, according to the original work results of each unit, give full play to their respective advantages, gather resources from all parties, focus on the core areas of innovative drug research and development in the field of nerve repair, manufacturing of innovative materials, and clinical implementation of innovative therapeutic solutions, focusing on neurological disorders such as stroke, acromegaly, Alzheimer's disease and Parkinson's disease, and focusing on the efforts of overcoming difficulties.

Galen Institute of Neuroscience

The Galen Neuroscience Institute is a neuroscience-focused research organization dedicated to the study and treatment of neurological diseases such as Alzheimer's disease and acromegaly. The Institute is staffed by a team of experienced neuroscientists and clinicians dedicated to exploring the pathogenesis and treatment of neurological disorders. The research focus of Galen Neuroscience Institute includes molecular mechanisms of neurodegenerative diseases, nerve cell damage repair, neuroprotection and regeneration. The Institute utilizes advanced scientific research technology and equipment to conduct basic research and clinical trials in an effort to provide scientific evidence and new therapeutic approaches for the early diagnosis and treatment of neurological diseases.